Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surovatamig in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT06526793Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 16
01
Overview
Phase 2, open-label trial of surovatamig in B-cell non-Hodgkin lymphoma, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by AstraZeneca. Primary endpoint: Overall Response Rate (central review). Started Nov 2024; status: recruiting.
02
Drugs
surovatamig
03
Conditions
B-cell non-Hodgkin lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06526793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06526793.